• Prescribing Information
  • Patient Information
  • Patient Site
  • Phase III Study Primary Endpoint*
    Phase III Study Secondary Endpoints*
    Phase III Study: Other Endpoints*
    Infant Study: Exploratory Endpoint**

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    Savings & Support

    Copay Cards

    *Eligible patients pay as little as $10

    Terms and Conditions apply

    Download Copay Cards

    ** This is an optional area where footnotes can live.

    * Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,800. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Cost and Coverage

    Favorable access on many plans nationwide and is available at the lowest branded copay for many commercial and Medicare patients.

    View eligibility

    Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,800. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    Help your patients with access to EUCRISA

    Visit Eucrisa for you

    Patient Forms

    Download helpful forms to share with your patients at the links below.

    What to Expect Downloadable PDF

    Patient Brochure

    Telemedicine FAQs

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.